Procurement comparison
dHACM vs. Synthetic Skin Substitutes: Procurement Decision Framework
dHACM allografts and synthetic skin substitutes occupy overlapping but distinct positions on most wound care formularies. This guide frames the procurement decision in terms of reimbursement pathway, evidence base, and supply chain risk — not just clinical preference.
| Attribute | dHACM | Synthetic |
|---|---|---|
| Regulatory pathway | Section 361 HCT/P | 510(k) device |
| Typical reimbursement | Q-coded, ASP+6% | Mixed (Q-code or bundled) |
| Storage | Ambient (lyophilized) or –80 °C | Ambient or refrigerated |
| Primary indications | DFU, VLU, chronic ulcers | Burns, surgical reconstruction, DFU |
| Supply chain | Tissue donation + processor | Manufactured |
| Typical unit price range | $$–$$$ | $$–$$$$ |
Regulatory pathway
dHACM products are regulated as Section 361 HCT/Ps and do not require 510(k) clearance. Most synthetic skin substitutes are 510(k)-cleared devices. The pathway affects how you document medical necessity and which payer LCD language applies.
Reimbursement coverage
dHACM products carry Q-codes (Q4101–Q4205 range) with established Medicare ASP-based reimbursement and broad MAC LCD coverage for DFU and VLU. Synthetic substitutes vary widely — some carry Q-codes, some bill under wound dressing HCPCS codes, and some are bundled into facility payment.
Evidence base
Both categories have RCT-level evidence in chronic DFU. dHACM carries deeper published evidence in lower-extremity diabetic and venous ulcers. Synthetic substitutes have stronger evidence in burn and surgical reconstruction. Match the evidence to your case mix.
Supply chain risk
dHACM supply depends on placental tissue donation pipelines and AATB-accredited processing. Synthetic substitutes depend on manufacturer production capacity and raw material supply. Both categories have seen episodic shortages in the past three years — second-source both wherever possible.
Bottom line for procurement
Wound centers focused on diabetic and venous ulcers typically standardize on dHACM as the primary skin substitute and use synthetic options for burn or reconstructive cases. Multi-source both categories to manage shortage risk.
Last updated: 2026-06-28